Genomic Biomarker Market Analysis, Size, Trends And Forecast During 2021-2028
![]() |
Genomic Biomarker Market |
Genomic
biomarkers are characteristics of DNA and RNA that are utilized as markers for
disease, tools for describing the condition, and tools for choosing a course of
treatment. The body's response to treatment or other treatments, as well as
pathological and physiological processes, are all represented by it. The Genomic Biomarker Market is benefiting
from the healthcare sector's increased use of novel medications, increased
R&D efforts to diagnose chronic illnesses, and rising use of minimally
invasive procedures.
Along
with positive government initiatives connected to genetic research, the growing
emphasis on the availability of personalized medicine for enabling improved
patient care is enhancing the growth prognosis for the global Genomic Biomarker Market. When it comes
to identifying and diagnosing COVID-19 disease, biomarkers are crucial. The
growth estimate for the global market is also being boosted by supportive
government initiatives related to genetic research and the increased emphasis
on the availability of personalized medications for enabling improved patient
care.
The Genomic
Biomarker Market Is Anticipated To Reach US$ 4,396.6 Mn In 2021 And
Is Projected To Grow At A CAGR Of 9.5% From 2021 To 2028.
Companion
diagnostics and biomarkers are being used more frequently in medical practices,
which ultimately results in more targeted disease-specific diagnosis, care, and
treatment. As a result, both pharmaceutical firms and healthcare providers have
increased their demand for genetic biomarkers, which has a substantial impact
on the growth of the global Genomic
Biomarker Market. Another factor that is anticipated to positively affect
market expansion is the increased demand for genetic biomarkers in prostate
cancer.
Competitive Landscape
The
global Genomic Biomarker Market participants
are Thermo Fisher Scientific, F. Hoffmann-La Roche AG, Liquid Genomics, Inc.,
AROS Applied Biotechnology A/S, Myriad Genetics, Inc., QIAGEN, Eurofins
Scientific, Genomic Health, Bio-Rad Laboratories, Inc., Epigenomics AG, and
Aepodia
Genomic Biomarker Market Trends
Increased Adoption of Personalized
Medicine: Genomic biomarkers
play a crucial role in personalized medicine, enabling healthcare providers to
tailor treatments based on an individual's genetic profile. This approach
offers more effective and targeted therapies, leading to better patient
outcomes.
Advancements in Genomic
Technologies: The field of genomics
has seen rapid technological advancements, such as Next-Generation Sequencing
(NGS), CRISPR-Cas9 gene editing, and single-cell genomics. These innovations
have led to reduced sequencing costs, improved accuracy, and the discovery of
novel biomarkers.
Growing Applications in Oncology: Genomic
Biomarker Market have shown
immense potential in cancer diagnosis, prognosis, and treatment selection. As
cancer is a leading cause of mortality worldwide, the integration of genomic
biomarkers in oncology has significant implications for patient care.
Biomarkers in Infectious Diseases: Genomic biomarkers have been increasingly used in
the diagnosis and management of infectious diseases. They can help identify
specific pathogens, determine drug resistance profiles, and track the spread of
infections.
Comments
Post a Comment